English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

on-β2” (IFN-β2) in 1980 and subsequently cloned and assigned the human gene to chromosome 7. By 1988 this cytokine, also independently discovered by several other investigators, was dubbed “interleukin-6” (IL-6). Already in 1988-1989 we discovered that IL-6 was an almost invariant presence at the host-tumor interface in a variety of human solid tumors with both the tumor cells and stromal elements showing strong-tomoderate IL-6 immunoreactivity. The early studies also showed that circulating IL-6 was commonly increased in cancer patients and that glucocorticoids and estradiol-17β inhibited the IL-6 promoter. Today, the contributions of IL-6/STAT3 signaling have emerged as central to the interplay between infection and cancer, in promoting cancer metastases (e.g. breast, colon, liver) and in explaining genderand obesity-related bias in cancer incidence (e.g. of liver cancer – less in women compared to males but high in obesity). Moreover, the well-known aging-related increase in cancer incidence is also now increasingly explained in terms of a “senescent secretory phenotype” which includes the increased production of IL-6 by tumor, stromal and infiltrating cells. Indeed, our early data (1991-1993) showing that cancer-derived mutants of p53 upregulated the IL-6 promoter, in contrast to wild-type (wt) p53 and wt Rb which inhibited, already pointed to a mechanism for dysregulated autocrine production of IL-6 by cancer cells – a mechanism that has since been extended by others. Additionally, it was shown already in 1989-1994 by Tamm and colleagues that IL-6 affected the “social” behavior of breast cancer cells – increased motility, cell-cell and cell-substrate dyshesion and epithelial-tomesenchymal transformation. That these effects underlie the ability of paracrine or autocrine IL-6 to enhance the invasiveness and metastasis ability of tumor cells is now evident in animal models. In addition to the “canonical”, i.e. transcriptional functions of IL-6-activated STAT3, recent observations on the IL-6induced targeting of activated Tyr-phosphorylated STAT3 to cytoplasmic sequestering endosomes and the involvement of non-Tyr-phospho rylated STAT3 in regulating microtubule dynamics, Ras-mediated cell transformation and tumorigenicity, and mitochondrial respiration highlight novel “non-canonical” functions of STAT3 in the cytoplasm of cancer cells.

Thirty years after “interferon-β2: interleukin-6 at the host-tumor interface